irofulven has been researched along with Adenocarcinoma, Basal Cell in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chimmani, R; Gurram, M; Kelner, MJ; McMorris, TC; Staake, MD | 1 |
| Alisala, K; Banda, G; Chimmani, R; Kelner, MJ; McMorris, TC; Staake, MD | 1 |
| Kelner, MJ; McMorris, TC; Staake, MD | 1 |
| Blessing, JA; Pearl, ML; Rose, PG; Schilder, RJ | 1 |
| Arsenau, J; Berman, B; MacDonald, JR; Richards, D; Senzer, N; Smith, S | 1 |
| Beale, P; Boyer, M; Chan, AT; Chung, HC; Clarke, S; Goh, BC; Ho, R; Jeung, HC; Lam, KC; Lim, R; Ma, B; Mo, FK; Ng, EK; Ong, SY; Rha, SY; Roh, JK; Soo, R; Yeo, W; Zee, B | 1 |
| Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R | 1 |
| Estes, L; Kelner, MJ; McMorris, TC; Samson, KM; Taetle, R; Wang, W | 1 |
| Herman, TS; MacDonald, JR; Roberts, K; Woynarowska, BA; Woynarowski, JM | 1 |
| Kashimoto, S; MacDonald, JR; Nakano, K; Sato, Y | 1 |
3 trial(s) available for irofulven and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Sesquiterpenes; Treatment Outcome; Vomiting | 2004 |
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Survival Analysis | 2005 |
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Infusions, Intravenous; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Sesquiterpenes; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2007 |
7 other study(ies) available for irofulven and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Synthesis and antitumor activity of amine analogs of irofulven.
Topics: Adenocarcinoma; Amines; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Humans; Inhibitory Concentration 50; Molecular Structure; Sesquiterpenes; Structure-Activity Relationship | 2007 |
Structure-activity studies of urea, carbamate, and sulfonamide derivatives of acylfulvene.
Topics: Adenocarcinoma; Animals; B-Lymphocytes; Carbamates; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Lung Neoplasms; Mice; Sesquiterpenes; Spiro Compounds; Structure-Activity Relationship; Sulfonamides; Urea | 2010 |
Synthesis and biological activity of enantiomers of antitumor irofulven.
Topics: Acylation; Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Mice; Molecular Structure; Sesquiterpenes; Stereoisomerism; Structure-Activity Relationship | 2004 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome | 2008 |
Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Sesquiterpenes; Transplantation, Heterologous | 1996 |
Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents, Alkylating; Apoptosis; Combined Modality Therapy; DNA Damage; Gamma Rays; Humans; Intestinal Mucosa; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Sesquiterpenes; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Humans; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Sesquiterpenes; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2001 |